This document is a USPTO patent application (US20260083783A1) filed by the University of Cincinnati, detailing engineered probiotics capable of expressing anti-inflammatory molecules. The application describes a modified E. coli bacterium, potentially a probiotic like E. coli Nissle 1917, engineered to express a specific microbial anti-inflammatory molecule (MAM) protein and a related plasmid.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signals potential future developments in therapeutic biotechnology. Companies involved in probiotic development, biotechnology, or the production of anti-inflammatory treatments should monitor the progress of this patent and related research for potential licensing opportunities or competitive insights.